Artivion’s (AORT) “Buy” Rating Reaffirmed at Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They currently have a $58.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 41.12% from the stock’s current price.

Several other equities analysts also recently commented on AORT. Citizens Jmp upped their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Canaccord Genuity Group reiterated a “buy” rating and set a $51.00 price objective on shares of Artivion in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. JMP Securities lifted their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Finally, Wall Street Zen cut Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.11.

Artivion Trading Up 0.8%

Shares of Artivion stock traded up $0.33 during trading on Monday, reaching $41.10. 116,703 shares of the company were exchanged, compared to its average volume of 293,262. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -171.25 and a beta of 1.59. The business has a 50-day moving average price of $44.80 and a 200-day moving average price of $42.32. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.Artivion’s quarterly revenue was up 18.9% compared to the same quarter last year. Sell-side analysts anticipate that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, CAO Amy Horton sold 4,572 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $44.42, for a total transaction of $203,088.24. Following the sale, the chief accounting officer owned 130,058 shares in the company, valued at $5,777,176.36. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 47,376 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the transaction, the senior vice president directly owned 44,753 shares in the company, valued at $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 234,511 shares of company stock valued at $10,612,452 over the last quarter. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Artivion

Several large investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd grew its stake in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Artivion in the 3rd quarter worth approximately $27,000. USA Financial Formulas increased its position in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares during the last quarter. Finally, KBC Group NV purchased a new position in Artivion during the 4th quarter valued at $65,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.